Nauman Wazir1, Muhammad Fahad Arshad2, John Finney3, Katie Kirk4, Shivani Dewan1. 1. Department of Diabetes and Endocrine, Doncaster Royal Infirmary and Bassetlaw Teaching Hospitals, Doncaster DN2 5LT, UK. 2. Department of Diabetes and Endocrine, Sheffield Teaching Hospitals, Sheffield, UK. 3. Department of Nutrition and Dietics, Doncaster Royal Infirmary and Bassetlaw Teaching Hospitals, Doncaster DN2 5LT, UK. 4. Department of Surgery, Doncaster Royal Infirmary and Bassetlaw Teaching Hospitals, Doncaster DN2 5LT, UK.
Abstract
OBJECTIVE: To determine the influence of bariatric surgery on remission of type 2 diabetes mellitus (T2DM) in obese patients along with improvements in other obesity-associated comorbidities. STUDY DESIGN: Observational study. PLACE AND DURATION OF STUDY: Doncaster and Bassetlaw NHS Trust, UK, from August 2010 to August 2018. METHODOLOGY: All the cases of bariatric surgery in obese patients with T2DM who had completed 2 years of follow up were included in the study. Remission of T2DM was defined as glycated hemoglobin (HbA1C) <48 mmol/mol (<6.5%) or fasting blood sugar of <7.0 mmol/L, not on hypoglycemic agents 2 years after having bariatric surgery. Student's t-test was used to see any difference in baseline HbA1C, BMI, percentage of weight loss, and duration of diabetes between remitters and non-remitters. RESULTS: Two years follow-up data after bariatric surgery for remission of T2DM or otherwise was available for (n=121) patients. Majority (70.2%, n=85) were females and (29.8%, n=36) were males. Mean age was 48.21 ±9.77 years. Eightythree (68.6%) patients achieved remission of T2DM at 2 years and 31.4% (n=38) did not. Remission of other comorbidities was 33.3% (n=53 out of 159) for hypertension (HTN), 50.8% (n=60 out of 118) for dyslipidemia, 67.2% (n=43 out of 64) for obstructive sleep apnea (OSA), 52.1% (n=37 out of 71) for gastro esophageal reflux disease (GERD), 25.7% (n=18 out of 70) for asthma, and 23.3% (n=24 out of 103) for depression. CONCLUSION: Bariatric surgery effectively achieves remission of T2DM and other obesity associated comorbidities.
OBJECTIVE: To determine the influence of bariatric surgery on remission of type 2 diabetes mellitus (T2DM) in obesepatients along with improvements in other obesity-associated comorbidities. STUDY DESIGN: Observational study. PLACE AND DURATION OF STUDY: Doncaster and Bassetlaw NHS Trust, UK, from August 2010 to August 2018. METHODOLOGY: All the cases of bariatric surgery in obesepatients with T2DM who had completed 2 years of follow up were included in the study. Remission of T2DM was defined as glycated hemoglobin (HbA1C) <48 mmol/mol (<6.5%) or fasting blood sugar of <7.0 mmol/L, not on hypoglycemic agents 2 years after having bariatric surgery. Student's t-test was used to see any difference in baseline HbA1C, BMI, percentage of weight loss, and duration of diabetes between remitters and non-remitters. RESULTS: Two years follow-up data after bariatric surgery for remission of T2DM or otherwise was available for (n=121) patients. Majority (70.2%, n=85) were females and (29.8%, n=36) were males. Mean age was 48.21 ±9.77 years. Eightythree (68.6%) patients achieved remission of T2DM at 2 years and 31.4% (n=38) did not. Remission of other comorbidities was 33.3% (n=53 out of 159) for hypertension (HTN), 50.8% (n=60 out of 118) for dyslipidemia, 67.2% (n=43 out of 64) for obstructive sleep apnea (OSA), 52.1% (n=37 out of 71) for gastro esophageal reflux disease (GERD), 25.7% (n=18 out of 70) for asthma, and 23.3% (n=24 out of 103) for depression. CONCLUSION: Bariatric surgery effectively achieves remission of T2DM and other obesity associated comorbidities.
Authors: Michelle M C Tan; Xingzhong Jin; Craig Taylor; Adrian K Low; Philip Le Page; David Martin; Ang Li; David Joseph; Nic Kormas Journal: J Clin Med Date: 2022-07-31 Impact factor: 4.964